fbpx

Vertex’s CRISPR Gene Therapy Lands Another FDA Nod In A Rare Blood Disease

The FDA approved Vertex Pharmaceuticals’ gene therapy Casgevy for treating beta thalassemia, an inherited blood disease that leads to low levels of functioning hemoglobin. Last month, the one-time treatment won its first FDA nod for treating sickle cell disease.

The post Vertex’s CRISPR Gene Therapy Lands Another FDA Nod In A Rare Blood Disease appeared first on Above the Law.

Related Articles

Responses

Your email address will not be published. Required fields are marked *